9:57 AM
 | 
Apr 02, 2018
 |  BC Extra  |  Clinical News

Early stop in liver disease trial boosts MediciNova

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) shares rose Monday on news it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis showed that the product met the primary endpoint of reducing mean serum triglycerides. The company said it will...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >